Zurich Cantonal Bank
KLDO

Zurich Cantonal Bank’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Zurich Cantonal Bank’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,651
Closed -$31K – 2958
2021
Q3 		$31K Buy
5,651
+41
+0.7% +$254 ﹤0.01% 2737
2021
Q2 		$42K Buy
5,610
+100
+2% +$709 ﹤0.01% 2491
2021
Q1 		$45K Buy
+5,510
New +$60K ﹤0.01% 2420

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Zurich Cantonal Bank's KLDO Position: Q4 2021 in Review

Zurich Cantonal Bank sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2021, closing a stake of 5,651 shares — an estimated $31K sold.

Zurich Cantonal Bank first reported a position in KLDO in Q1 2021 and held it in 3 quarters. The position peaked at $45K in Q1 2021. 66 funds tracked by Wall St. Rank hold KLDO as of Q4 2021.

  • Zurich Cantonal Bank reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Zurich Cantonal Bank sold 5,651 Kaleido Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $31K.
  • Zurich Cantonal Bank first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Zurich Cantonal Bank's Kaleido Biosciences, Inc. Common Stock position peaked at $45K in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2021.

Based on Zurich Cantonal Bank's 13F filing for Q4 2021, filed 1 Feb 2022.